Linked Life Data

6086772

Source:http://linkedlifedata.com/resource/pubmed/id/6086772

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1984-8-27
pubmed:abstractText
The humoral response to herpes simplex virus (HSV) was examined in 21 patients with primary HSV infection who were participating in a placebo-controlled trial of oral acyclovir as therapy for first-episode genital herpes. A standard microneutralization assay and a western blot analysis, which detects the antibody response to individual polypeptides of HSV types 1 and 2, were used. Placebo-treated, HSV type-2-infected patients typically responded to HSV type-2 polypeptides that had molecular masses of 125, 84, 68, 59, 46, and 40 kilodaltons. Treatment with acyclovir diminished the humoral response both to HSV, as measured by the type-specific neutralizing-antibody titer, and to specific polypeptides, especially those with molecular masses of 50-100 kilodaltons, a range that includes polypeptides with molecular masses corresponding to those of glycoproteins D and E of HSV.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0022-1899
pubmed:author
pubmed:issnType
Print
pubmed:volume
150
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7-13
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial